Antisense inhibitor of apoB synthesis: A new approach for severe hypercholesterolemia

From, by Sue Hughes

Johannesburg, South Africa – A novel agent that reduces LDL production by inhibiting apolipoprotein B (apoB) synthesis could be an effective therapy for patients with severe hypercholesterolemia, a new study suggests [1].

The product, mipomersen (ISIS Pharmaceuticals/Genzyme), an antisense inhibitor of apoB synthesis, showed impressive reductions in LDL cholesterol in patients with homozygous familial hypercholesterolemia (FH) in the phase 3 study published online March 13, 2010 in the Lancet. The drug is also in late-stage trials in patients with heterozygous FH and other forms of severe hypercholesterolemia. Continue reading